Trials / Unknown
UnknownNCT05200221
A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice
A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma (HCC) in Routine Clinical Practice
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a single center observational real-world study. It is planned to include 300 patients with unresectable hepatocellular carcinoma (uHCC) treated with Donafenib. The purpose of the study was to observe the effectiveness and safety of Donafenib in the real world.
Conditions
Timeline
- Start date
- 2022-01-19
- Primary completion
- 2024-01-30
- Completion
- 2024-03-30
- First posted
- 2022-01-20
- Last updated
- 2022-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05200221. Inclusion in this directory is not an endorsement.